Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced the Company, in partnership with its collaborators, will present data from its product candidates and process development activities with six oral and poster presentations at the upcoming 57th American Society of Hematology (ASH) Annual Meeting. Senior management will also review the data and provide an update on Juno’s ongoing clinical development strategy during an analyst and investor event and webcast.

The first of two oral presentations will report updated data from the ongoing trial of JCAR014 in adults with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). This translational clinical research trial focuses on how optimization of the pharmacokinetics or exposure of JCAR014 relates to clinical outcomes. The second presentation will discuss the implications of prior allogeneic stem cell transplant and achievement of minimal residual disease negative complete remission in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) treated with JCAR015. Additionally, initial data from the anti-CD22 chimeric-antigen receptor (CAR) product candidate in pediatric and young adult relapsed or refractory ALL will be highlighted in one of four poster presentations.

“The clinical data in ALL, NHL, and CLL continue to be encouraging. The response rates and durability of responses across a range of B cell malignancies provide important insights on how persistence and depth of response translate into improved clinical outcomes, and are applicable to our portfolio broadly,” said Hans Bishop, Juno’s President and Chief Executive Officer. “We are also looking forward to the first presentation of early results from the anti-CD22 CAR study in pediatric ALL patients, a study which appears to be of increasing relevance with the ongoing emergence, particularly in pediatric patients, of CD19 epitope loss with treatment.” (Original Source)

Shares of Juno Therapeutics closed today at $56.39, up $0.06 or 0.11%. JUNO has a 1-year high of $69.28 and a 1-year low of $33. The stock’s 50-day moving average is $51.74 and its 200-day moving average is $48.05.

On the ratings front, Juno has been the subject of a number of recent research reports. In a report issued on November 18, Goldman Sachs analyst Salveen Richter initiated coverage with a Hold rating on JUNO and a price target of $50, which implies a downside of 11.0% from current levels. Separately, on October 29, Standpoint Research’s Ronnie Moas downgraded the stock to Hold .

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Salveen Richter and Ronnie Moas have a total average return of 31.4% and 7.3% respectively. Richter has a success rate of 68.6% and is ranked #72 out of 3649 analysts, while Moas has a success rate of 70.4% and is ranked #20.

Juno Therapeutics Inc is a biopharmaceutical company. The Company is engaged in revolutionizing medicine by re-engaging the body’s immune system to treat cancer.